{"id":"NCT01934010","sponsor":"Auris Medical, Inc.","briefTitle":"AM-101 in the Treatment of Post-Acute Tinnitus 1","officialTitle":"AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) - an Open-Label Extension to the TACTT2 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06","primaryCompletion":"2017-01","completion":"2017-01","firstPosted":"2013-09-04","resultsPosted":"2018-03-09","lastUpdate":"2018-05-16"},"enrollment":260,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Tinnitus"],"interventions":[{"type":"DRUG","name":"AM-101","otherNames":[]}],"arms":[{"label":"AM-101 injection","type":"EXPERIMENTAL"}],"summary":"The purpose of this research study is to test the safety and local tolerance of repeated treatment cycles of AM-101.","primaryOutcome":{"measure":"Frequency of Subjects With a Deterioration of Hearing Threshold at Day 35 (Air Conduction)","timeFrame":"Day 1 (TV1) to Day 35 (FUV2) of cycle 1","effectByArm":[{"arm":"1 Cycle AM-101","deltaMin":10,"sd":null},{"arm":"2 Cycles AM-101","deltaMin":2,"sd":null},{"arm":"3 Cycles AM-101","deltaMin":2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.128"},{"comp":"OG000 vs OG002","p":"0.075"},{"comp":"OG001 vs OG002","p":"1"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":114},"commonTop":["Ear pain","Headache","Ear discomfort","Hypoacusis","Nasopharyngitis"]}}